Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer
ID: 1-9 Jun 2010
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Premenopausal women with hormone receptor-positive early-stage invasive breast cancer.
Intended Guideline Users
Clinicians and others involved in the care of the target population.
- How does adjuvant ovarian ablation (OA) as systemic therapy improve clinically meaningful outcomes (disease-free survival, overall survival, quality of life and toxicity) when compared with and/or added to other systemic therapies, specifically chemotherapy and tamoxifen? As there are a number of ways that OA may be compared with or added to other systemic therapy, the following specific comparisons are addressed by this practice guideline:
- OA alone versus no systemic therapy
- OA plus chemotherapy versus chemotherapy alone
- OA alone versus chemotherapy alone
- OA alone versus tamoxifen alone
- OA plus tamoxifen versus tamoxifen alone
- OA plus tamoxifen and chemotherapy versus tamoxifen and chemotherapy
- OA plus tamoxifen versus chemotherapy alone
- OA plus tamoxifen versus no systemic therapy
- OA plus tamoxifen and chemotherapy versus chemotherapy alone
- What is the best way to ablate or suppress ovarian function: surgical oophorectomy, ovarian irradiation, or medical suppression?
Full Report (PDF) (918.72 KB)